JP2006504632A - チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤 - Google Patents

チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤 Download PDF

Info

Publication number
JP2006504632A
JP2006504632A JP2003587813A JP2003587813A JP2006504632A JP 2006504632 A JP2006504632 A JP 2006504632A JP 2003587813 A JP2003587813 A JP 2003587813A JP 2003587813 A JP2003587813 A JP 2003587813A JP 2006504632 A JP2006504632 A JP 2006504632A
Authority
JP
Japan
Prior art keywords
carbazole
dione
hydroxy
pyrrolo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003587813A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン ブース リチャード
アレクサンダー デニー ウイリアム
ミラ ドブルシン エレン
ジョン クラカー アラン
ヘレン ミッチェル ローナ
ブルース スモーイル ジェフリー
マーク トンプソン アンドゥリュー
フアト リー ホ
オリヴァー ジョセフ マッカシー フローレンス
デスモンド パルマー ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2006504632A publication Critical patent/JP2006504632A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2003587813A 2002-04-26 2003-04-15 チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤 Pending JP2006504632A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37580602P 2002-04-26 2002-04-26
PCT/IB2003/001417 WO2003091255A1 (en) 2002-04-26 2003-04-15 Inhibitors of checkpoint kinases (wee1 and chk1)

Publications (1)

Publication Number Publication Date
JP2006504632A true JP2006504632A (ja) 2006-02-09

Family

ID=29270703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587813A Pending JP2006504632A (ja) 2002-04-26 2003-04-15 チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤

Country Status (7)

Country Link
EP (1) EP1501831A1 (pt)
JP (1) JP2006504632A (pt)
AU (1) AU2003224341A1 (pt)
BR (1) BR0309783A (pt)
CA (1) CA2483496A1 (pt)
MX (1) MXPA04010617A (pt)
WO (1) WO2003091255A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073719A1 (ja) * 2008-12-26 2010-07-01 国立大学法人京都大学 Ｅｇ５阻害剤
WO2010098367A1 (en) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
WO2015115355A1 (ja) 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 抗がん剤組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219784A (zh) 2005-03-29 2011-10-19 艾科斯有限公司 可用于抑制chk1的杂芳基脲衍生物
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
CA2703489A1 (en) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
CN105622431A (zh) * 2011-01-28 2016-06-01 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5166204A (en) * 1989-11-01 1992-11-24 Toyama Chemical Co., Ltd. Isoindole derivatives and salts thereof and antitumor agent comprising the same
EP0695755B1 (en) * 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073719A1 (ja) * 2008-12-26 2010-07-01 国立大学法人京都大学 Ｅｇ５阻害剤
WO2010098367A1 (en) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
JP2012518598A (ja) * 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
WO2015115355A1 (ja) 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 抗がん剤組成物
JPWO2015115355A1 (ja) * 2014-01-31 2017-03-23 カルナバイオサイエンス株式会社 抗がん剤組成物
US9974795B2 (en) 2014-01-31 2018-05-22 Carna Biosciences, Inc. Anticancer agent composition

Also Published As

Publication number Publication date
EP1501831A1 (en) 2005-02-02
MXPA04010617A (es) 2004-12-13
AU2003224341A1 (en) 2003-11-10
BR0309783A (pt) 2005-03-22
CA2483496A1 (en) 2003-11-06
WO2003091255A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
RU2136683C1 (ru) Сконденсированные с гетероциклическим кольцом производные пиримидина
US6395733B1 (en) Heterocyclic ring-fused pyrimidine derivatives
CN107614503B (zh) 稠环或三环芳基嘧啶化合物用作激酶抑制剂
ES2235769T3 (es) Pirrolocarbazoles fusionados.
EP1556384B1 (en) Pyrimido compounds having antiproliferative activity
KR100597505B1 (ko) 4-아미노-6-페닐-피롤로[2,3-ｄ]피리미딘 유도체
WO1998023613A1 (en) Fused bicyclic pyrimidine derivatives
HU218950B (hu) Kondenzált imidazo-piridin-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2018090939A1 (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
PL199615B1 (pl) Pochodne imidazo [1,2-a] pirydyny i pirazolo [2,3-a] pirydyny, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowania
JP2006504632A (ja) チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤
HRP950033A2 (en) Tricyclic compounds capable of inhibiting tryosine kinases of the epidermal growth factor receptor family
CA2700903A1 (en) Parp inhibitor compounds
KR101561756B1 (ko) 이미다조 피라진
CA2775942A1 (en) Pi3k (delta) selective inhibitors
SK286805B6 (sk) Kondenzované pyrolokarbazoly a izoindolóny, farmaceutická kompozícia s ich obsahom, ich použitie a spôsob inhibície aktivity trk kinázy
Capps et al. 2-(Aminoalkyl)-5-nitropyrazolo [3, 4, 5-kl] acridines, a new class of anticancer agents
KR20080098043A (ko) Ｅｇ5 키네신 조절제로서의 인돌로피리딘
CN111566100B (zh) 嘧啶类化合物、其制备方法及其医药用途
KR20080103977A (ko) Ｅｇ５ 키네신 조절자로서 인돌로피리딘
JP2011530574A (ja) ２−アルキル−６−シクロアミノ−３−（ピリジン−４−イル）イミダゾ［１，２−ｉｂ］ピリダジン誘導体、この調製およびこの治療応用
WO2004111060A1 (en) IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
WO2020077944A1 (zh) 嘌呤系列衍生物及其制备方法和用途
US7094798B1 (en) Inhibitors of checkpoint kinases (Wee1 and Chk1)
CN115448921B (zh) 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100308